Technology | Clinical Decision Support | December 22, 2015

American College of Cardiology Broadens Mobile Clinical App Collection

TAVR, anticoagulation apps available to support clinicians in providing quality patient care

December 22, 2015 — The American College of Cardiology (ACC) has launched a new Society of Thoracic Surgeons (STS)/ACC Transcatheter Aortic Valve Replacement (TAVR) In-Hospital Mortality Risk App and an extensively overhauled the ACC AnticoagEvaluator App, bolstering its expansive Clinical App Collection. With these new and improved apps, the ACC continues to diversify the clinical content and decision support it offers clinicians in the mobile space.

The STS/ACC TAVR In-Hospital Mortality Risk App assists clinicians in determining the predicted in-hospital mortality risk of a patient who is considering TAVR as a treatment option for aortic valve replacement. Clinicians can evaluate a patient’s mortality risk and compare it to the national average based on STS/ACC TVT Registry data. This app marks ACC’s first effort in building mobile risk applications for the ACC National Cardiovascular Data Registry (NCDR) using NCDR data and is part of ACC’s efforts to use NCDR data to improve the quality of cardiovascular care.

The AnticoagEvaluator has been completely redesigned to be more user friendly and offer additional support, including recommendations from the 2013 ACC/AHA/HRS Atrial Fibrillation Guideline. The app helps clinicians make well-informed decisions on antithrombotic therapy for non-valvular atrial fibrillation patients by allowing them to calculate a patient's renal function and risk of ischemic stroke, blood clot and bleed; generate individualized risk for antithrombotic therapy options based on individual clinical trials; and improve accurate use of direct oral anticoagulants with renal-function-adjusted dosage based on prescribing information. The app now also includes Edoxaban on the list of available anticoagulant therapies and the Cockcroft-Gault equation for calculating renal function.

The ACC will continue to expand its Clinical App Collection in 2016 with offerings based on new clinical pathways documents, appropriate use criteria, additional guideline releases, NCDR risk models and other sources. All ACC apps are free and can be found by searching their titles in the iTunes or GooglePlay app stores.

Up-to-date information about ACC’s full mobile Clinical App Collection can be found at www.acc.org/mobileresources#Clinical.

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init